A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
To read the full story
Related Article
- Expert Panel Report Failed to Delve into Annual Price Cuts, Irking Pharma Officials
June 30, 2023
- Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
June 7, 2023
- Expert Panel to Propose Setting Up Requirements for Generic Entry to Ensure Stable Supplies; Draft Report Due Out June 6
June 5, 2023
- Expert Panel Wants to See Action on Excessive Yakkasa, No Direction on Buffer Zone: Draft Report
June 5, 2023
- Expert Panel Pushes Fresh Evaluation Approach for New Drug Pricing, Rethink of Spillovers: Draft Report
June 5, 2023
REGULATORY
- Govt Must Not Let Pro-Innovation Reform of 2024 Go to Waste: Sr Vice Minister
January 15, 2025
- Nothing Decided on Drug Discovery Support Fund: Minister
January 15, 2025
- MHLW Calls for Proper Use and Ordering of Flu Drugs amid Outbreak
January 14, 2025
- MHLW Starts Inviting Subsidy Applications for Ramp-Up of Key Drugs
January 14, 2025
- MHLW Plans to Submit 6 Bills in 2025 Ordinary Diet Session
January 14, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…